3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Virus Diseases
1
Tumor Virus Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
Cisplatin
9
pembrolizumab
8
Radiotherapy, Intensity-Modulated
6
Radiotherapy
5
Carboplatin
5
cemiplimab
4
Paclitaxel
4
durvalumab
3
Surveys and Questionnaires
3
Nivolumab
3
tremelimumab
2
Taxes
2
Radiation
2
olaparib
1
niraparib
1
lirilumab
1
linrodostat
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
bavituximab
1
atezolizumab
1
alpha-2'-deoxythioguanosine
1
aldesleukin
1
Tiragolumab
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Image-Guided
1
Proton Therapy
1
Platinum Compounds
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Squamous Cell
×
Nimorazole
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled